Specifically, we explored the impact of changes in pharmacokinetic parameters such as the of the 177Lu-PSMA-binding association rate, internalization rates into normal and tumor cells, binding rates to serum proteins, and release rates from cells. The gene discussed is FOLH1; the disease is neoplasm.